Oman's pharmaceutical market looks bright
Oman: Wednesday, March 19 - 2008 at 08:50
Oman's pharmaceutical market will grow in the short to medium term, supported by excellent healthcare facilities, which are continuing to receive attention from foreign investors, according to a report by Research and Markets. Prescription and patented drugs are expected to remain the dominant products within the overall market, at 97% and 92% of the total value, respectively. Their position will be retained by an affluent population, modernisation of healthcare facilities and the development of the private sector. On the other hand, cost-containment policies promoted by the government will encourage the development of the over-the-counter and generics sectors. The government is presently considering the introduction of a faster generics approval process for Indian-made products, which are increasingly present in the GCC.
- ADD ARTICLE TO
-
Facebook
del.icio.us
Digg">
Also consider reading:
- » Pfizer to set up UAE research centre
- » Julphar to open new plants
- » Sex pills sold over the counter
- » Healthcare for all in Qatar
- » BinSina launches hi-tech health campaign
- » Oman to build $1bn healthcare city
- » Healthy bones campaign launched
- » e-TQM offers health masters course
- » Fewer UAE nationals seek care abroad
- » Maternity hospital for Sharjah
Jeff Florian, Senior ReporterWednesday, March 19 - 2008 at 08:50 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Index : Healthcare
Browse related articles
Browse related articlesToday's most read articles:
Most read articles the past week:
Disclaimer:
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
Web Feeds